相关实验视频

Updated: May 16, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

小细胞肺癌:一个回顾

So Yeon Kim¹, Henry S Park², Anne C Chiang¹

¹Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.

|March 31, 2025

概括

小细胞肺癌是一种与吸烟有关的癌症,存活率很低. 目前的治疗方法结合化疗和免疫疗法,

科学领域:

癌症学
肺病学
医学瘤学

背景情况:

小细胞肺癌 (SCLC) 是一种侵袭性神经内分泌瘤,主要与吸烟有关,其5年生存率很低.
每10万人中有4.7人患上SCLC,95%的病例与吸烟有关.
患者经常出现呼吸道症状或无症状转移,通过活检确认诊断.

研究的目的:

总结目前对SCLC发病率,风险因素,临床表现,病期和治疗情况的了解.
突出一线和二线治疗的最新进展,无论是有限阶段 (LS-SCLC) 还是广泛阶段 (ES-SCLC).

主要方法:

目前关于SCLC的文献和临床数据的综述.
对治疗结果的分析,包括生存率和对各种治疗方案的反应.
用于治疗分层,将SCLC分为有限阶段 (LS-SCLC) 和广泛阶段 (ES-SCLC).

主要成果:

经过手术或化疗和免疫治疗,LS- SCLC 的生存率有所改善 (durvalumab 的中位生存率高达 55. 9 个月).
对ES-SCLC的第一线治疗包括用PD-L1抑制剂 (杜尔瓦卢马布/ 阿特索利祖马布) 进行乙化疗,瘤缩小了60- 70%,但平均存活时间为12- 13个月.
对于ES-SCLC的第二线选择包括lurbinectedin和tarlatamab,提供适度的反应率和无进展的生存率.

结论:

乳腺癌仍然是一个重大的健康挑战,特别是在晚期.
化学疗法和免疫疗法是目前的LS-SCLC和ES-SCLC治疗标准.
新兴的治疗方法如lurbinectedin和tarlatamab为复发性/耐药性ES-SCLC提供了新的途径.

更多相关视频

Acellular and Cellular Lung Model to Study Tumor Metastasis

Acellular and Cellular Lung Model to Study Tumor Metastasis

Published on: August 19, 2018

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...